A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
Gabriella MacchiaRoberta LazzariNicoletta ColomboConcetta LalisciaGiovanni CapelliGiuseppe Roberto D'AgostinoFrancesco DeodatoErnesto MaranzanoEdy IppolitoSara RonchiFabiola PaiarMarta ScorsettiSavino CillaRossana IngargiolaAlessandra HuscherAnna Maria CerrottaAndrei FodorLisa VicenziDonatella RussoSimona BorghesiElisabetta PerrucciSandro PignataCynthia AristeiAlessio Giuseppe MorgantiGiovanni ScambiaVincenzo ValentiniBarbara Alicja Jereczek-FossaGabriella FerrandinaPublished in: The oncologist (2019)
This study aimed to define activity and safety of stereotactic body radiotherapy (SBRT) in a very large, real life data set of patients with metastatic, persistent, recurrent ovarian cancer (MPR-OC). Patient age <60 years, PTV <18 cm3 , lymph node disease, and biologically effective dose α/β10 >70 Gy were associated with higher chance of complete response (CR). Achievement of CR and total dose >25 Gy were associated with better local control (LC) rate. Mild toxicity was experienced in 20.7% of patients. In conclusion, this study confirms the activity and safety of SBRT in MPR-OC patients and identifies clinical and treatment parameters able to predict CR and LC rate.